A position statement published in Egyptian Rheumatology and Rehabilitation argues that the Trabecular Bone Score, a texture measure extracted from routine dual-energy X-ray absorptiometry images, should now be treated as a clinical necessity rather than an optional research add-on in osteoporosis care. The statement, issued by the Egyptian Academy of Bone and Muscle Health, synthesizes evidence published up to January 15, 2026, following a PRISMA-guided search of PubMed/MEDLINE, Embase, Scopus and the Cochrane Library. Of 101 articles reviewed, 22 studies met the eligibility criteria, and TBS emerged as an independent predictor of incident fracture in 20 of those 22 studies. The authors frame their argument around a shift from a bone-quantity-only model, based on bone mineral density, toward a dual model that also accounts for bone quality.
The clinical problem the statement addresses is what the authors call the sensitivity gap of bone mineral density. DXA-derived BMD has long been the gold standard for osteoporosis diagnosis, but a substantial proportion of fragility fractures occur in people whose T-scores fall in the osteopenic range, between −1.0 and −2.5, or even in the normal range, a phenomenon described as the osteoporosis paradox. Bone strength, the authors argue, is a composite of quantity and quality: microarchitecture, turnover and mineralization. TBS addresses the quality pillar by analyzing the spatial distribution of pixel gray levels in the lumbar spine DXA image, providing an indirect but validated assessment of trabecular microarchitecture that distinguishes dense, well-connected bone from porous, fragile bone without additional scan time or radiation dose.
One of the most consequential applications is in the osteopenic grey zone. By mapping BMD T-scores against TBS categories on a dual-axis reclassification matrix, clinicians can reclassify roughly 25 to 30 percent of patients, according to the statement. A patient with osteopenia but a degraded TBS carries a fracture risk comparable to that of a patient whose T-score falls in the osteoporotic range. In the updated standards described, a degraded TBS in an osteopenic patient is often considered a valid justification for initiating pharmacological therapy, particularly when other clinical risk factors are present. The statement emphasizes, however, that the impact of TBS-adjusted FRAX is most pronounced for patients positioned near regional intervention thresholds, such as those set by NOGG, rather than drastically altering risk categories for everyone.
Integration into FRAX, the Fracture Risk Assessment Tool, is a central theme. Traditional FRAX combines major clinical risk factors, such as age, glucocorticoid use and parental fracture history, with femoral neck BMD to estimate ten-year fracture probability, but it does not directly capture bone microarchitecture. Because TBS behaves as an independent risk factor, adjusting FRAX with TBS yields a more comprehensive skeletal assessment. Large population-based analyses cited in the statement show that TBS adjustment produces only modest increases in overall discrimination, such as small gains in the area under the curve, while its primary clinical strength lies in net reclassification, capturing vulnerable patients with discordant bone density and quality.
The statement devotes particular attention to secondary osteoporosis, where BMD can be deceptively reassuring. In type 2 diabetes, patients often have normal or even high BMD yet suffer significantly higher fragility fracture rates, attributed to the accumulation of advanced glycation end-products and impaired bone turnover. TBS is consistently lower in diabetic patients than in non-diabetics even when BMD is matched, making it, in the authors’ view, the preferred adjunct for fracture risk assessment in this population. Similar reasoning applies to primary hyperparathyroidism, where TBS reveals early trabecular degradation of the lumbar spine before T-scores drop into the osteoporotic range, and a degraded TBS can serve as a marker of target organ damage informing parathyroidectomy decisions in asymptomatic patients.
Glucocorticoid-induced osteoporosis presents another setting where TBS outpaces conventional densitometry. Clinical studies summarized in the statement show that TBS decreases significantly faster than BMD in patients on prednisone or similar treatments, because glucocorticoids cause rapid apoptosis of osteoblasts and increased osteoclast activity, producing a swift decline in trabecular connectivity. Since fracture risk rises almost immediately after starting glucocorticoids, long before measurable mineral loss appears on DXA, the authors describe a degraded TBS alongside a normal T-score as a hallmark of the condition and argue that TBS is vital for early intervention. In chronic kidney disease, where vascular calcifications and degenerative spinal disease can falsely elevate lumbar spine BMD, TBS is less susceptible to these artifacts and can refine fracture risk stratification, though the statement is explicit that it cannot differentiate histological subtypes of renal osteodystrophy, for which bone biopsy remains the gold standard.
Men represent an under-researched but clinically important population. Although men typically present with higher BMD than women, approximately 20 to 25 percent of all hip fractures occur in males, frequently with higher mortality and morbidity. The statement reports that low TBS is a potent independent predictor of major osteoporotic fractures in men, providing predictive value beyond BMD, age and clinical risk factors, and that men with low TBS face significantly higher vertebral fracture risk even when their T-scores remain normal or osteopenic. Adding TBS to FRAX in many male patients shifts their ten-year fracture probability upward, often moving them from the low-risk to the treatment-recommended category, and TBS is described as particularly valuable for men on androgen deprivation therapy for prostate cancer or chronic glucocorticoids, where rapid microarchitectural loss is not immediately captured by BMD.
Technical evolution occupies a substantial portion of the document. Early TBS algorithms were sensitive to attenuation from overlying soft tissue, sometimes underestimating scores in patients with high body mass index. Version 4.0 software incorporates direct correction for tissue thickness over the region of interest, improving reliability and reproducibility, which matters for longitudinal monitoring and for ethnicity-specific reference databases, since groups differ in BMI distribution and fat storage patterns. A renormalized L1-only model now permits reliable TBS assessment based solely on the first lumbar vertebra when lower vertebrae are excluded for degenerative changes, effectively rescuing scans in patients with severe osteoarthritis or scoliosis, though the L1 vertebra should be excluded if it differs from L2 by more than one T-score unit or if a fracture is present.
Treatment monitoring with TBS requires careful methodology. The least significant change for TBS is generally higher than for BMD, typically between 3.0 and 5.0 percent depending on institutional precision studies and scan quality, and serial comparisons are valid only on the same densitometer hardware with identical software versions. Responsiveness varies by drug class: osteoanabolic agents such as romosozumab and teriparatide produce significant measurable TBS increases, frequently exceeding 3 to 5 percent over 12 to 24 months under Version 4.0 evaluation; long-term denosumab shows progressive moderate improvements; and oral bisphosphonates typically yield stability or modest gains of 1 to 2 percent, where a stable TBS itself signals successful maintenance of trabecular connectivity.
The statement also surveys emerging technology while flagging its limits. TBS-Reveal, an AI-powered evolution of the software, aims to evaluate bone microarchitecture opportunistically from routine DXA scans and plain X-rays integrated into PACS workflows, generating color-coded heatmaps that could identify focal zones of degradation. Preliminary validation analyses report promising initial accuracy and specificity, but the authors caution that widespread adoption and guideline integration await larger longitudinal outcome studies. The document is equally candid about TBS itself: it is an indirect, two-dimensional texture index rather than a direct threeD measurement, it is not endorsed as a universal screening tool for the general population, and its thresholds require attention to sex, age, ethnicity and local normative data. Its greatest value, the authors conclude, lies in selected patients near intervention thresholds and in secondary osteoporosis, where seeing the architecture behind the density can change management.
Subject of Research: Clinical integration of trabecular bone score into osteoporosis diagnosis and fracture risk assessment
Article Title: Clinical integration of trabecular bone score in precision osteoporosis care: a position statement by the Egyptian academy of bone and muscle health
Article References: El Miedany, Y., Toth, M., Plummer, S., Mahran, S., Elwakil, W., El Miedany, A., & El Yassaki, A. (2026). Clinical integration of trabecular bone score in precision osteoporosis care: a position statement by the Egyptian academy of bone and muscle health. Egyptian Rheumatology and Rehabilitation, 53(1), Article 74. https://doi.org/10.1186/s43166-026-00444-7
Image Credits: AI Generated
DOI: 10.1186/s43166-026-00444-7
Keywords: trabecular bone score, osteoporosis, DXA, bone mineral density, FRAX, fracture risk, bone quality, secondary osteoporosis, type 2 diabetes, glucocorticoid-induced osteoporosis, TBS-Reveal, position statement
News Source: Ophelia Keating. (October 29, 2026). Trabecular Bone Score Moves From Research Tool to Osteoporosis Care Standard. Scienmag.
